Literature DB >> 2611496

Endothelium-dependent vasodilator effects of platelet activating factor on rat resistance vessels.

K Kamata1, T Mori, K Shigenobu, Y Kasuya.   

Abstract

1. To elucidate the mechanisms of the powerful and long-lasting hypotension produced by platelet activating factor (PAF), its effects on perfusion pressure in the perfused mesenteric arterial bed of the rat were examined. 2. Infusion of PAF (10(-11) to 3 x 10(-10) M; EC50 = 4.0 x 10(-11) M; 95%CL = 1.6 x 10(-11) - 9.4 x 10(-11) M) and acetylcholine (ACh) (10(-10) to 10(-6) M; EC50 = 3.0 +/- 0.1 x 10(-9) M) produced marked concentration-dependent vasodilatations which were significantly inhibited by treatment with detergents (0.1% Triton X-100 for 30 s or 0.3% CHAPS for 90 s). 3. Pretreatment with CV-6209, a PAF antagonist, inhibited PAF- but not ACh-induced vasodilation. 4. Treatment with indomethacin (10(-6) M) had no effect on PAF- or ACh-induced vasodilatation. 5. These results demonstrate that extremely low concentrations of PAF produce vasodilatation of resistance vessels through the release of endothelium-derived relaxing factor (EDRF). This may account for the strong hypotension produced by PAF in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2611496      PMCID: PMC1854812          DOI: 10.1111/j.1476-5381.1989.tb12685.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist.

Authors:  D A Handley; R G Van Valen; M K Melden; S Flury; M L Lee; R N Saunders
Journal:  Immunopharmacology       Date:  1986-08

2.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators).

Authors:  C A Demopoulos; R N Pinckard; D J Hanahan
Journal:  J Biol Chem       Date:  1979-10-10       Impact factor: 5.157

3.  Potentiation by bovine serum albumin (BSA) of endothelium-dependent vasodilator response to acetyl glyceryl ether phosphorylcholine (AGEPC).

Authors:  K Shigenobu; Y Tanaka; T Maeda; Y Kasuya
Journal:  J Pharmacobiodyn       Date:  1987-05

4.  CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.

Authors:  Z Terashita; Y Imura; M Takatani; S Tsushima; K Nishikawa
Journal:  J Pharmacol Exp Ther       Date:  1987-07       Impact factor: 4.030

5.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.

Authors:  R F Furchgott; J V Zawadzki
Journal:  Nature       Date:  1980-11-27       Impact factor: 49.962

6.  Mechanism(s) of the hypotensive effect of synthetic 1-O-octadecyl-2-O-acetyl-glycero-3-phosphorylcholine.

Authors:  T Kamitani; M Katamoto; M Tatsumi; K Katsuta; T Ono; H Kikuchi; S Kumada
Journal:  Eur J Pharmacol       Date:  1984-03-02       Impact factor: 4.432

7.  The release of platelet-activating factor from human endothelial cells in culture.

Authors:  G Camussi; M Aglietta; F Malavasi; C Tetta; W Piacibello; F Sanavio; F Bussolino
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

8.  Studies on the hypotensive effects of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits, and dogs.

Authors:  S Tanaka; Y Kasuya; Y Masuda; K Shigenobu
Journal:  J Pharmacobiodyn       Date:  1983-11

9.  Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium.

Authors:  S Moncada; A G Herman; E A Higgs; J R Vane
Journal:  Thromb Res       Date:  1977-09       Impact factor: 3.944

10.  Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes.

Authors:  J M Mencia-Huerta; J Benveniste
Journal:  Eur J Immunol       Date:  1979-05       Impact factor: 5.532

View more
  6 in total

1.  Involvement of nitric oxide pathway in the PAF-induced relaxation of rat thoracic aorta.

Authors:  H Moritoki; T Hisayama; S Takeuchi; H Miyano; W Kondoh
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

2.  Mechanisms of platelet activating factor-induced changes in sheep tracheal blood flow.

Authors:  D R Corfield; S E Webber; J G Widdicombe
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

3.  Renal response to anaphylaxis in anesthetized rats and isolated perfused rat kidneys: roles of nitric oxide.

Authors:  Kiyotaka Mukai; Yuhichi Kuda; Toshishige Shibamoto; Mamoru Tanida; Yasutaka Kurata; Hitoshi Yokoyama
Journal:  J Physiol Sci       Date:  2017-12-05       Impact factor: 2.781

4.  Vasodilator and constrictor actions of platelet-activating factor in the isolated microperfused afferent arteriole of the rabbit kidney. Role of endothelium-derived relaxing factor/nitric oxide and cyclooxygenase products.

Authors:  L A Juncos; Y L Ren; S Arima; S Ito
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

5.  Possible involvement of endothelium-derived hyperpolarizing factor (EDHF) in the depressor responses to platelet activating factor (PAF) in rats.

Authors:  Y Tanaka; S Hayakawa; T Imai; A Akutsu; H Hirano; H Tanaka; T Nakahara; K Ishii; K Shigenobu
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

6.  Involvement of nitric oxide and eicosanoids in platelet-activating factor-induced haemodynamic and haematological effects in dogs.

Authors:  K Noguchi; T Matsuzaki; N Shiroma; Y Ojiri; M Sakanashi
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.